Literature DB >> 24681345

Epidemiology and outcomes of bloodstream infection in patients with cirrhosis.

Michele Bartoletti1, Maddalena Giannella1, Paolo Caraceni1, Marco Domenicali1, Simone Ambretti2, Sara Tedeschi1, Gabriella Verucchi1, Lorenzo Badia1, Russell E Lewis1, Mauro Bernardi1, Pierluigi Viale3.   

Abstract

BACKGROUND & AIMS: Bloodstream infections (BSIs) in cirrhotic patients are 10-fold more common than in non-cirrhotic patients and increasingly caused by resistant pathogens. We examined 162 BSI episodes in cirrhotic patients to describe the etiology and risk factors for 30-day mortality.
METHODS: We retrospectively analyzed all consecutive BSIs in patients with liver cirrhosis at our 1350-bed teaching hospital (January 2008 to June 2012). Cox-proportional hazard regression was used to analyze the impact of disease and treatment-related variables on the crude 30-day mortality.
RESULTS: BSI episodes were identified in 162 patients, including 29 mixed infections. Most of episodes were classified as hospital acquired or healthcare associated (93%). Gram-negative bacteria (GNB), Gram-positive bacteria and Candida spp. caused 64%, 38%, and 10% of episodes, respectively. GNB were classified as multi-drug resistant (MDR) and extensively drug resistant (XDR) in 25% and 21% of cases, respectively. The overall crude 30-day mortality rate was 29%. Four risk factors were independently associated with 30-day crude mortality: worsening of MELD score from baseline (the last MELD score available in the 2 weeks prior BSI) to that at BSI onset (HR 1.11 per point increase, 95% CI 1.07-1.15, p<0.0001), spontaneous bacterial peritonitis as BSI source (HR 4.42, 2.04-9.54, p=0.002), sepsis grading (HR 2.18, 1.39-3.43, p=0.0007), and inappropriate antibiotic therapy within 24h from blood cultures (HR 2.82, 1.50-5.41, p=0.002).
CONCLUSION: An increasing proportion of BSIs in cirrhotic patients are caused by resistant GNB and Candida spp. Accurate evaluation of risk factors for mortality may improve early appropriate therapeutic management.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bloodstream infection; Candidemia; Extremely-drug resistance; Inappropriate empirical therapy; Liver cirrhosis; Mortality; Multi-drug resistance

Mesh:

Year:  2014        PMID: 24681345     DOI: 10.1016/j.jhep.2014.03.021

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  43 in total

1.  Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis.

Authors:  Sonja Lang; Yi Duan; Jinyuan Liu; Manolito G Torralba; Claire Kuelbs; Meritxell Ventura-Cots; Juan G Abraldes; Francisco Bosques-Padilla; Elizabeth C Verna; Robert S Brown; Victor Vargas; Jose Altamirano; Juan Caballería; Debbie Shawcross; Michael R Lucey; Alexandre Louvet; Philippe Mathurin; Guadalupe Garcia-Tsao; Samuel B Ho; Xin M Tu; Ramon Bataller; Peter Stärkel; Derrick E Fouts; Bernd Schnabl
Journal:  Hepatology       Date:  2019-08-20       Impact factor: 17.425

2.  Epidemiological characteristics of bloodstream infections in patients with different degrees of liver disease.

Authors:  Micaela Brandolini; Marta Corbella; Annalisa De Silvestri; Carmine Tinelli; Giulia Albonico; Riccardo Albertini; Serena Ludovisi; Raffaele Bruno; Piero Marone; Lorenzo Minoli; Elena Seminari
Journal:  Infection       Date:  2015-05-15       Impact factor: 3.553

Review 3.  Liver - guardian, modifier and target of sepsis.

Authors:  Pavel Strnad; Frank Tacke; Alexander Koch; Christian Trautwein
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

Review 4.  Hepatosplanchnic circulation in cirrhosis and sepsis.

Authors:  Meghan Prin; Jan Bakker; Gebhard Wagener
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

5.  Association Between Intravenous Fluid Bolus and Biomarker Trajectory During Prehospital Care.

Authors:  Emily B Brant; Jason Kennedy; Christian Martin-Gill; Vanessa Jackson; Octavia M Peck Palmer; Clifton W Callaway; Jeremy M Kahn; Donald M Yealy; Derek C Angus; Christopher W Seymour
Journal:  Prehosp Emerg Care       Date:  2019-07-01       Impact factor: 3.077

6.  Infective endocarditis in patients with hepatic diseases.

Authors:  E Seminari; A De Silvestri; V Ravasio; S Ludovisi; R Utili; N Petrosillo; F Castelli; M Bassetti; F Barbaro; P Grossi; N Barzaghi; M Rizzi; L Minoli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-12-21       Impact factor: 3.267

Review 7.  Bloodstream infections in patients with liver cirrhosis.

Authors:  Michele Bartoletti; Maddalena Giannella; Russell Edward Lewis; Pierluigi Viale
Journal:  Virulence       Date:  2016-02-11       Impact factor: 5.882

Review 8.  Epidemiology and management of healthcare-associated bloodstream infections in non-neutropenic immunosuppressed patients: a review of the literature.

Authors:  Nursel Calik Basaran; Sibel Ascioglu
Journal:  Ther Adv Infect Dis       Date:  2017-10-17

9.  Bacterial Infections Change Natural History of Cirrhosis Irrespective of Liver Disease Severity.

Authors:  Elena Dionigi; Matteo Garcovich; Mauro Borzio; Gioacchino Leandro; Avik Majumdar; Aikaterini Tsami; Vasiliki Arvaniti; Davide Roccarina; Massimo Pinzani; Andrew K Burroughs; James O'Beirne; Emmanuel A Tsochatzis
Journal:  Am J Gastroenterol       Date:  2017-02-21       Impact factor: 10.864

10.  Relationship Between Etiology of Cirrhosis and Survival Among Patients Hospitalized in Intensive Care Units.

Authors:  Chansong Choi; Dae Hee Choi; Grant M Spears; Thoetchai Bee Peeraphatdit; Laura Piccolo Serafim; Ognjen Gajic; Patrick S Kamath; Vijay H Shah; Alice Gallo de Moraes; Douglas A Simonetto
Journal:  Mayo Clin Proc       Date:  2022-01-25       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.